RESUMO
Studies were performed using 80 children aged 1-3 years with lesions to mental development. Patients were divided into three groups according to the severity and structure of lesions of mental development: those most strongly characterized by delayed speech development (group 1), those with delayed mental development due to organic CNS lesions (group 2), and those with abnormal mental development and high levels of psychopathological symptoms (group 3). There were significant increases (p < 0.001) in blood levels of autoantibodies to nerve growth factor (NGF) in children in each of these groups as compared with a control group (0.75 +/- 0.24 OD units). The levels of anti-NGF autoantibodies increased from group 1 to group 3 (0.95 +/- 0.24 OD units in group 1, 1.13 +/- 0.27 OD units in group 2. and 1.24 +/- 0.4 OD units in group 3). These correlations suggest that the level of anti-NGF autoantibodies can, taken in conjunction with a number of other parameters, be regarded as a potential molecular marker demonstrating abnormal development of the nervous system.
Assuntos
Autoanticorpos/análise , Deficiências do Desenvolvimento/imunologia , Fator de Crescimento Neural/imunologia , Pré-Escolar , Feminino , Humanos , Técnicas Imunoenzimáticas , Lactente , MasculinoAssuntos
Autoanticorpos/análise , Fatores de Crescimento Neural/metabolismo , Esquizofrenia/metabolismo , Adolescente , Criança , Pré-Escolar , Feminino , Proteína Glial Fibrilar Ácida/metabolismo , Humanos , Masculino , Fatores de Crescimento Neural/sangue , Proteínas S100/metabolismo , Psicologia do EsquizofrênicoRESUMO
Studies were performed on 54 patients with different types of schizophrenia-paranoid (8), recurrent-progressive (30), and slowly progressive (16), with ICD-10 rubrics F20.00 and F20.01, F20.22 and F20.02, and F21 respectively. An immunoenzyme method was used to demonstrate that schizophrenia patients had elevated levels of autoantibody to nerve growth factor, by a factor of 1.5 compared with a group of 70 healthy subjects. The autoantibody level was related to the stage of disease: during the active phase, there was a significant increase compared with patients in remission (1.38 +/- 0.26 and 0.92 +/- 0.25 U respectively). There were no differences between variants with different disease courses. The authors suggest that the data obtained here indicate that the autoantibody level can be used as a measure of the activity of the disease process.
